This article is a correction to:
Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China
Yaohui Jiang
Jun Xie*
- Department Cardiology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
A Corrigendum on
by Jiang Y and Xie J. (2022) Front. Cardiovasc. Med. 9:946399. doi: 10.3389/fcvm.2022.946399
In the published article, there was an error in the affiliation. Instead of “Department of Cardiology, Drum Tower Hospital, Nanjing University Medical School, Nanjing, China”, it should be “Department of Cardiology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: empagliflozin, heart failure with preserved ejection fraction, cost-effectiveness analysis, China, pharmaco economic
Citation: Jiang Y and Xie J (2023) Corrigendum: Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China. Front. Cardiovasc. Med. 10:1205721. doi: 10.3389/fcvm.2023.1205721
Received: 14 April 2023; Accepted: 24 April 2023;
Published: 9 May 2023.
Approved by: Frontiers in Cardiovascular Medicine, Frontiers Media SA, Switzerland
© 2023 Jiang and Xie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jun Xie xiejun20192022@163.com